Lotus Pharmaceutical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	20,509	18,584	16,958	14,633	12,649
Revenue Growth (YoY)	10.36%	9.59%	15.89%	15.68%	17.90%
Cost of Revenue	8,603	7,660	7,574	6,827	7,009
Gross Profit	11,907	10,924	9,384	7,806	5,640
Selling, General & Admin	4,983	4,133	3,764	3,141	2,703
Research & Development	724.31	613.9	541.46	419.01	373.84
Operating Expenses	5,700	4,744	4,302	3,557	3,112
Operating Income	6,207	6,180	5,082	4,249	2,529
Interest Expense	-877.68	-561.39	-533.69	-356.22	-266.69
Interest & Investment Income	114.51	101.44	31.55	3.51	5.34
Currency Exchange Gain (Loss)	16.78	168.11	91.67	-81.22	-119.23
Other Non Operating Income (Expenses)	95.54	28.89	23.94	-10.31	1.78
EBT Excluding Unusual Items	5,556	5,917	4,696	3,805	2,150
Gain (Loss) on Sale of Investments	548.28	604.16	715.05	286.81	-
Gain (Loss) on Sale of Assets	-13.72	-0.7	-24.75	2.52	-3.2
Asset Writedown	-303.02	-159.99	-179.37	-138.26	-233.18
Other Unusual Items	-69.45	-0.91	-103.79	-16	-43.42
Pretax Income	5,718	6,360	5,103	3,940	1,870
Income Tax Expense	998.12	1,294	997.3	919.46	466.65
Earnings From Continuing Operations	4,720	5,066	4,106	3,021	1,403
Net Income	4,720	5,066	4,106	3,021	1,403
Net Income to Common	4,720	5,066	4,106	3,021	1,403
Net Income Growth	-6.82%	23.38%	35.91%	115.25%	36.68%
Shares Outstanding (Basic)	260	262	261	261	255
Shares Outstanding (Diluted)	262	263	262	262	257
Shares Change (YoY)	-0.67%	0.53%	0.13%	1.95%	5.43%
EPS (Basic)	18.14	19.35	15.72	11.59	5.50
EPS (Diluted)	18.04	19.23	15.67	11.54	5.47
EPS Growth	-6.19%	22.72%	35.79%	110.97%	29.62%
Free Cash Flow	6,162	5,801	1,204	3,142	-453.07
Free Cash Flow Per Share	23.55	22.02	4.59	12.01	-1.76
Dividend Per Share	2.560	5.730	4.660	3.460	1.930
Dividend Growth	-55.32%	22.96%	34.68%	79.27%	451.43%
Gross Margin	58.05%	58.78%	55.34%	53.35%	44.59%
Operating Margin	30.26%	33.25%	29.97%	29.04%	19.99%
Profit Margin	23.01%	27.26%	24.21%	20.64%	11.09%
Free Cash Flow Margin	30.05%	31.21%	7.10%	21.47%	-3.58%
EBITDA	7,609	7,331	6,171	5,094	3,204
EBITDA Margin	37.10%	39.45%	36.39%	34.81%	25.33%
D&A For EBITDA	1,402	1,151	1,088	844.44	675.77
EBIT	6,207	6,180	5,082	4,249	2,529
EBIT Margin	30.26%	33.25%	29.97%	29.04%	19.99%
Effective Tax Rate	17.46%	20.35%	19.54%	23.34%	24.95%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.